查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798010

2032 年注意力不足过动症治疗市场预测：按药物类型、治疗类型、给药途径、分销管道、年龄层、技术和地区进行的全球分析

Attention Deficit Hyperactivity Disorder Treatment Market Forecasts to 2032 - Global Analysis By Drug Type, Therapy Type, Route of Administration, Distribution Channel, Age Group, Technology and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球注意力不足过动症(ADHD) 治疗市场预计在 2025 年达到 262.097 亿美元，到 2032 年将达到 482.209 亿美元，预测期内的复合年增长率为 9.1%。

注意力不足过动症(ADHD) 的治疗涉及多种方法，旨在控制注意力不集中、衝动和过动等核心症状。这些方法包括使用兴奋剂和非兴奋剂药物、行为疗法、认知训练和教育介入。主要目标是提高注意力，减少衝动行为，并增强不同年龄层（包括儿童、青少年和成人）ADHD 患者的日常功能。

根据世界卫生组织（WHO）的数据，截至2022年10月18日，全球冠状病毒（COVID-19）确诊病例已超过622,389,418例。

提高认识和早期筛检工作

大众对过动症（ADHD）和其他神经多样性障碍的认识正在稳步提高，从而促进了早期诊断和更积极的治疗方法。教育宣传活动和倡导工作正在帮助减少对过动症的污名化，并鼓励家庭寻求专业协助。医疗保健系统正在采用更广泛的筛检通讯协定，以便在更年轻的时候发现过动症的症状。这种转变推动了对专业诊断工具和个人化护理计划的需求。包括人工智慧评估在内的技术进步，使早期检测更加准确，也更加便利。政府的支持和政策改革正在进一步加速学校和诊所早期筛检倡议的实施。

长期治疗费用高昂

治疗过动症通常需要持续的心理治疗、药物和行为支持，这给许多家庭带来了经济负担。数年累积的治疗费用可能会阻碍持续的护理，尤其是在低收入社区。过动症相关服务的保险覆盖范围仍然不稳定，进一步加重了经济负担。此外，高昂的费用限制了人们获得先进治疗方法和能够改善治疗效果的数位工具。儘管对多动症综合解决方案的需求日益增长，但这种经济障碍正在减缓市场成长。

非药物治疗的发展

人们对药物相关副作用的担忧日益加剧，促使人们对非药物治疗过动症（ADHD）的方法越来越感兴趣，包括认知行为疗法、神经反馈和数位疗法。这些替代疗法对患者和看护者颇具吸引力，因为它们副作用较少，并且可以根据个人需求进行客製化。与远端医疗平台的整合使得这些治疗可以远距进行，从而扩大医疗资源匮乏地区的覆盖范围。行动应用程式和游戏化干预措施因其引人入胜且用户友好的模式而日益流行。随着对个人化和更​​安全治疗方案的需求不断增长，非药物疗法代表着一个充满希望的成长领域。

对误诊和过度诊断的担忧

过动症 (ADHD) 的症状通常与其他疾病的症状重迭，导致准确诊断困难且容易出错。过度依赖主观评估可能导致误诊和不恰当的治疗方案。在某些情况下，正常的行为改变会被误认为是 ADHD，进而引发伦理和医学的担忧。过度诊断会增加医疗成本，并导致不必要的用药。这些问题可能会削弱人们对诊断工具的信心，并延迟上市。

COVID-19的影响：

新冠疫情加速了过动症（ADHD）评估和治疗工具向数位化的转变。封锁和保持社交距离的措施扰乱了传统的面对面评估，推动了远端医疗服务的快速普及。远端平台使过动症患者能够获得持续的护理，即使在危机期间也能确保护理的连续性。疫情也凸显了扩充性的心理健康解决方案的重要性，从而增加了对数位化治疗的投资。行动应用程式和线上疗法作为诊所护理的便捷替代方案，越来越受到关注。

预测期内，兴奋剂市场预计将成为最大的市场

兴奋剂类药物预计将在预测期内占据最大的市场占有率，这得益于其在症状管理方面的有效性。这些药物包括哌甲酯和安非他命，被广泛使用，并得到了大量临床研究的支持。它们能够改善注意力、衝动控制和执行功能，使其成为过动症（ADHD）治疗的基石。儘管有副作用的担忧，兴奋剂仍然是许多患者的第一线治疗药物。配方的不断创新正在提高安全性并降低滥用的可能性。随着认知度和诊断率的提高，对兴奋剂类药物治疗的需求预计将保持强劲。

预计行动医疗应用将在预测期内实现最高的复合年增长率

预计行动医疗应用领域将在预测期内呈现最高成长率。这些应用为使用者提供了便利的治疗、监控和教育资源取得途径，尤其适合年轻使用者。游戏化锻炼、提醒和进度追踪等功能提升了使用者的参与度和依从性。与穿戴式装置和远端医疗平台的整合进一步增强了其实用性。随着数位素养的提高和智慧型手机普及率的提升，行动应用正成为过动症管理的重要工具。其扩充性和个人化使其成为拓展传统临床环境以外医疗服务的理想选择。

比最大的地区

由于人们对神经发育障碍的认识不断提高以及政府的支持措施，预计亚太地区将在预测期内占据最大的市场占有率。人工智慧筛检工具、行动应用程式和云端基础系统等技术进步正在提高诊断的准确性和治疗覆盖率。政府支持的措施、在地化内容和策略合作是塑造市场格局的关键发展。热门趋势包括远端医疗医疗和互动治疗平台。医疗保健支出的不断增长，加上都市区的不断扩张，正在推动全部区域对客製化且可及的多动症治疗方案的需求。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高。这得益于其强大的医疗基础设施、较高的诊断率以及对心理健康计画的充足资金支持。该地区在采用人工智慧诊断和远端医疗平台等先进技术方面处于领先地位。教育机构和职场越来越多地整合过动症支持工具，以促进整体性。政府拨款和私人投资正在加速研究和产品开发。随着对个人化治疗和数位化解决方案的需求不断增长，北美仍然是一个充满活力且快速发展的过动症治疗市场。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球注意力不足过动症(ADHD) 治疗市场（依药物类型）

  • 兴奋剂
    • 安非他命
    • 哌甲酯
    • Lisdexamfetamine
    • 右哌甲酯
  • 无刺激性
    • 阿托西汀
    • 胍法辛
    • 可乐定
    • 安非他酮
  • 其他药物类型

6. 全球注意力不足过动症(ADHD) 治疗市场（依治疗类型）

  • 行为疗法
  • 家长培训
  • 认知行为治疗（CBT）
  • 社交技能培训
  • 饮食与营养

7. 全球注意力不足过动症(ADHD) 治疗市场（依给药途径）

  • 口服
  • 经皮
  • 其他的

8. 全球注意力不足过动症(ADHD) 治疗市场（按分销管道）

  • 医院药房
  • 零售药局
  • 网路药局
  • 专科诊所

9. 全球注意力不足过动症(ADHD) 治疗市场（按年龄层）

  • 孩子们
  • 青年
  • 成人

10. 全球注意力不足过动症(ADHD) 治疗市场（按技术）

  • 数位治疗学
  • 基于人工智慧的诊断工具
  • 游戏化认知训练
  • 行动医疗应用程式
  • 其他技术

11. 全球注意力不足过动症(ADHD) 治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：公司概况

  • Takeda Pharmaceutical
  • Neos Therapeutics
  • Novartis AG
  • KemPharm Inc.
  • Pfizer Inc.
  • NeuroSigma Inc.
  • Eli Lilly and Company
  • Rhodes Pharmaceuticals
  • Johnson & Johnson
  • Bausch Health Companies
  • Teva Pharmaceutical
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals
  • Corium Inc.
  • Supernus Pharmaceuticals
  • Ironshore Pharmaceuticals
  • Tris Pharma
  • Akili Interactive
  • Aytu BioPharma
  • Sun Pharmaceutical
Product Code: SMRC30380

According to Stratistics MRC, the Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market is accounted for $26209.70 million in 2025 and is expected to reach $48220.90 million by 2032 growing at a CAGR of 9.1% during the forecast period. Attention Deficit Hyperactivity Disorder (ADHD) treatment involves various approaches aimed at managing the core symptoms of inattention, impulsivity, and hyperactivity. These methods may include the use of stimulant or non-stimulant medications, behavioral therapies, cognitive training, and educational interventions. The primary objective is to help individuals with ADHD improve their attention span, reduce impulsive actions, and enhance daily functioning across different age groups, including children, teens, and adults.

According to the World Health Organization's report, manifestation of coronavirus (COVID-19) has resulted in more than 622,389,418 confirmed cases infected individuals worldwide as of 18 October, 2022.

Market Dynamics:

Driver:

Growing awareness and early screening initiatives

Public awareness of ADHD and other neurodiverse conditions is steadily increasing, leading to earlier diagnoses and more proactive treatment approaches. Educational campaigns and advocacy efforts have helped reduce stigma and encourage families to seek professional help. Healthcare systems are adopting broader screening protocols to identify ADHD symptoms at younger ages. This shift is driving demand for specialized diagnostic tools and personalized care plans. Technological advancements, including AI-powered assessments, are making early detection more accurate and accessible. Government support and policy reforms are further accelerating the adoption of early screening initiatives across schools and clinics.

Restraint:

High cost of long-term treatment

Managing ADHD often requires ongoing therapy, medication, and behavioral support, which can be financially burdensome for many families. The cumulative cost of treatment over several years can deter consistent care, especially in low-income regions. Insurance coverage for ADHD-related services remains inconsistent, adding to the financial strain. High costs also limit access to advanced therapies and digital tools that could improve outcomes. This economic barrier slows market growth despite rising demand for comprehensive ADHD solutions.

Opportunity:

Development of non-pharmacological treatments

Amid growing concerns over medication side effects, interest is rising in non-drug approaches to managing ADHD, such as cognitive behavioral therapy, neurofeedback, and digital therapeutics. These alternatives offer fewer side effects and can be tailored to individual needs, making them attractive to patients and caregivers. Integration with telehealth platforms allows remote delivery of these treatments, expanding access in underserved areas. Mobile apps and gamified interventions are gaining popularity for their engaging and user-friendly formats. As demand for personalized and safer options rises, non-pharmacological treatments present a promising growth area.

Threat:

Misdiagnosis or overdiagnosis concerns

ADHD symptoms often overlap with other conditions, making accurate diagnosis challenging and prone to error. Overreliance on subjective assessments can lead to misdiagnosis, resulting in inappropriate treatment plans. In some cases, normal behavioral variations are mistakenly labeled as ADHD, raising ethical and medical concerns. Overdiagnosis can inflate healthcare costs and contribute to unnecessary medication use. These issues undermine trust in diagnostic tools and may slow market adoption.

Covid-19 Impact:

The COVID-19 pandemic accelerated the shift toward digital ADHD assessment and treatment tools. Lockdowns and social distancing measures disrupted traditional in-person evaluations, prompting rapid adoption of telehealth services. Remote platforms enabled continued care for individuals with ADHD, ensuring treatment continuity during the crisis. The pandemic also highlighted the importance of scalable mental health solutions, leading to increased investment in digital therapeutics. Mobile apps and online therapy gained traction as accessible alternatives to clinic-based care.

The stimulants segment is expected to be the largest during the forecast period

The stimulants segment is expected to account for the largest market share during the forecast period, due to their proven efficacy in symptom management. These drugs, including methylphenidate and amphetamines, are widely prescribed and supported by extensive clinical research. Their ability to improve focus, impulse control, and executive functioning makes them a cornerstone of ADHD therapy. Despite concerns about side effects, stimulants remain the first-line treatment for many patients. Ongoing innovation in drug formulations is enhancing safety and reducing misuse potential. As awareness and diagnosis rates rise, the demand for stimulant-based therapies is projected to remain strong.

The mobile health applications segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mobile health applications segment is predicted to witness the highest growth rate. These apps offer convenient access to therapy, monitoring, and educational resources, especially for younger users. Features like gamified exercises, reminders, and progress tracking enhance user engagement and adherence. Integration with wearable devices and telehealth platforms further boosts their utility. As digital literacy improves and smartphone penetration increases, mobile apps are becoming a vital tool in ADHD management. Their scalability and personalization make them ideal for expanding care beyond traditional clinical settings.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, owing to rising awareness of neurodevelopmental disorders and supportive government initiatives. Technological advancements such as AI-powered screening tools, mobile applications, and cloud-based systems are improving diagnostic accuracy and treatment reach. Government-backed initiatives, localized content, and strategic collaborations are key developments shaping the landscape. Popular trends include telehealth-enabled care and interactive therapeutic platforms. Rising healthcare spending, coupled with urban expansion, is boosting demand for tailored and accessible ADHD treatment options throughout the region.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong healthcare infrastructure, high diagnosis rates, and robust funding for mental health programs. The region is a leader in adopting advanced technologies like AI-driven diagnostics and telehealth platforms. Educational institutions and workplaces are increasingly integrating ADHD support tools to promote inclusivity. Government grants and private investments are accelerating research and product development. With rising demand for personalized care and digital solutions, North America remains a dynamic and rapidly evolving market for ADHD treatment.

Key players in the market

Some of the key players in Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market include Takeda Pharmaceutical, Neos Therapeutics, Novartis AG, KemPharm Inc., Pfizer Inc., NeuroSigma Inc., Eli Lilly and Company, Rhodes Pharmaceuticals, Johnson & Johnson, Bausch Health Companies, Teva Pharmaceutical, Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals, Corium Inc., Supernus Pharmaceuticals, Ironshore Pharmaceuticals, Tris Pharma, Akili Interactive, Aytu BioPharma, and Sun Pharmaceutical.

Key Developments:

In July 2025, Pfizer Inc. announced the completion of a global, ex-China, licensing agreement with 3SBio, Inc. granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio's SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio's proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company's robust oncology pipeline.

In June 2025, Novartis announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the "Shares"), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

In September 2024, Takeda committed JPY4.6 billion to five new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda's focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce.

Drug Types Covered:

  • Stimulants
  • Non-Stimulants
  • Other Drug Types

Therapy Types Covered:

  • Behavioral Therapy
  • Parent Training
  • Cognitive Behavioral Therapy (CBT)
  • Social Skills Training
  • Diet and Nutrition

Routes of Administration Covered:

  • Oral
  • Transdermal
  • Others

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

Age Groups Covered:

  • Children
  • Adolescents
  • Adults

Technologies Covered:

  • Digital Therapeutics
  • AI-Based Diagnostic Tools
  • Gamified Cognitive Training
  • Mobile Health Applications
  • Other Technologies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Stimulants
    • 5.2.1 Amphetamines
    • 5.2.2 Methylphenidate
    • 5.2.3 Lisdexamfetamine
    • 5.2.4 Dexmethylphenidate
  • 5.3 Non-Stimulants
    • 5.3.1 Atomoxetine
    • 5.3.2 Guanfacine
    • 5.3.3 Clonidine
    • 5.3.4 Bupropion
  • 5.4 Other Drug Types

6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Behavioral Therapy
  • 6.3 Parent Training
  • 6.4 Cognitive Behavioral Therapy (CBT)
  • 6.5 Social Skills Training
  • 6.6 Diet and Nutrition

7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Transdermal
  • 7.4 Others

8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Clinics

9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Age Group

  • 9.1 Introduction
  • 9.2 Children
  • 9.3 Adolescents
  • 9.4 Adults

10 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Technology

  • 10.1 Introduction
  • 10.2 Digital Therapeutics
  • 10.3 AI-Based Diagnostic Tools
  • 10.4 Gamified Cognitive Training
  • 10.5 Mobile Health Applications
  • 10.6 Other Technologies

11 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Takeda Pharmaceutical
  • 13.2 Neos Therapeutics
  • 13.3 Novartis AG
  • 13.4 KemPharm Inc.
  • 13.5 Pfizer Inc.
  • 13.6 NeuroSigma Inc.
  • 13.7 Eli Lilly and Company
  • 13.8 Rhodes Pharmaceuticals
  • 13.9 Johnson & Johnson
  • 13.10 Bausch Health Companies
  • 13.11 Teva Pharmaceutical
  • 13.12 Mallinckrodt Pharmaceuticals
  • 13.13 Amneal Pharmaceuticals
  • 13.14 Corium Inc.
  • 13.15 Supernus Pharmaceuticals
  • 13.16 Ironshore Pharmaceuticals
  • 13.17 Tris Pharma
  • 13.18 Akili Interactive
  • 13.19 Aytu BioPharma
  • 13.20 Sun Pharmaceutical

List of Tables

  • Table 1 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 3 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Stimulants (2024-2032) ($MN)
  • Table 4 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Amphetamines (2024-2032) ($MN)
  • Table 5 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Methylphenidate (2024-2032) ($MN)
  • Table 6 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Lisdexamfetamine (2024-2032) ($MN)
  • Table 7 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Dexmethylphenidate (2024-2032) ($MN)
  • Table 8 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Non-Stimulants (2024-2032) ($MN)
  • Table 9 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Atomoxetine (2024-2032) ($MN)
  • Table 10 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Guanfacine (2024-2032) ($MN)
  • Table 11 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Clonidine (2024-2032) ($MN)
  • Table 12 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Bupropion (2024-2032) ($MN)
  • Table 13 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Other Drug Types (2024-2032) ($MN)
  • Table 14 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 15 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Behavioral Therapy (2024-2032) ($MN)
  • Table 16 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Parent Training (2024-2032) ($MN)
  • Table 17 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Cognitive Behavioral Therapy (CBT) (2024-2032) ($MN)
  • Table 18 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Social Skills Training (2024-2032) ($MN)
  • Table 19 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Diet and Nutrition (2024-2032) ($MN)
  • Table 20 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 21 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 22 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 23 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Others (2024-2032) ($MN)
  • Table 24 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 25 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 26 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 27 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 28 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 29 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 30 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Children (2024-2032) ($MN)
  • Table 31 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Adolescents (2024-2032) ($MN)
  • Table 32 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Adults (2024-2032) ($MN)
  • Table 33 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Technology (2024-2032) ($MN)
  • Table 34 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 35 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By AI-Based Diagnostic Tools (2024-2032) ($MN)
  • Table 36 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Gamified Cognitive Training (2024-2032) ($MN)
  • Table 37 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Mobile Health Applications (2024-2032) ($MN)
  • Table 38 Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Outlook, By Other Technologies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.